摘要
目的观察雷珠单抗玻璃体内注射治疗中心凹旁渗出性异常血管复合体(PEVAC)的临床效果。方法回顾性病例系列研究。分析2015年1月至2020年1月在夏邑县人民医院及河南省立眼科医院诊治的PEVAC 14例(14眼)的临床资料。所有患者接受3次雷珠单抗玻璃体内注射治疗。观察患者术前、术后1周、1个月及3个月的视力(BCVA)和中央视网膜厚度(CRT)。结果治疗前及治疗后各时间点之间视力差异均无统计学意义(F=0.73, P=0.541), 各时间点之间的CRT差异亦无统计学意义(F=34.76, P=0.672)。结论雷珠单抗玻璃体内注射治疗PEVAC无明显疗效。尚需探索发病原因及治疗方案。
Objective To observe the clinical efficacy of intravitreal injection for perifoveal exudative vascular anomalous complex(PEVAC).Methods This was a retrospective case series study.The clinical data of 14 eyes of 14 patients with PEVAC from Jan.2015 to Jan.2020 in the People’s Hospital of Xiayi Country and Henan Eye Hospital were analyzed.All patients received intravitreal injection of ranibizumab for three times.The best corrected visual acuity(BCVA)and central retinal thickness(CRT)were observed at preoperation,1 week,1 month and 3 months after operation.Results There was no significant difference in BCVA before and different time points after treatment(F=0.73,P=0.541).And there was no significant difference in CRT at different time points(F=34.76,P=0.672).Conclusion The intravitreal injection of ranibizumab for the treatment of PEVAC is invalid.The pathogenesis and treatment options still need to be explored.
作者
韩永杰
黄爱国
Han Yongjie;Huang Aiguo(Department of Ophthalmology,The People’s Hospital of Shangqiu Country,Shangqiu 476400,China;Department of Ophthalmology,Henan Eye Hospital,Zhengzhou 450006,China)
出处
《中华眼外伤职业眼病杂志》
2022年第4期311-314,共4页
Chinese Journal of Ocular Trauma and Occupational Eye Disease
